Phenotypic resistance to breast cancer therapy is predominantly due to defective hormone receptor signaling, drug efflux, and resistance to molecular pathway selective small-molecule pharmacological inhibitors, leading to a putative drug-resistant stem cell population. Here, NR4A1 is linked to breast carcinoma.